Department of Agricultural, Food, and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.
Medical Department, Justus-Liebig University Giessen, Giessen, Germany.
Adv Nutr. 2020 Mar 1;11(2):420-438. doi: 10.1093/advances/nmz074.
Observational studies provide strong evidence for the health benefits of dietary fiber (DF) intake; however, human intervention studies that supplement isolated and synthetic DFs have shown inconsistent results. Therefore, we conducted a systematic review to summarize the effects of DF supplementation on immunometabolic disease markers in intervention studies in healthy adults, and considered the role of DF dose, DF physicochemical properties, intervention duration, and the placebo used. Five databases were searched for studies published from 1990 to 2018 that assessed the effect of DF on immunometabolic markers. Eligible studies were those that supplemented isolated or synthetic DFs for ≥2 wk and reported baseline data to assess the effect of the placebo. In total, 77 publications were included. DF supplementation reduced total cholesterol (TC), LDL cholesterol, HOMA-IR, and insulin AUC in 36-49% of interventions. In contrast, <20% of the interventions reduced C-reactive protein (CRP), IL-6, glucose, glucose AUC, insulin, HDL cholesterol, and triglycerides. A higher proportion of interventions showed an effect if they used higher DF doses for CRP, TC, and LDL cholesterol (40-63%), viscous and mixed plant cell wall DFs for TC and LDL cholesterol (>50%), and longer intervention durations for CRP and glucose (50%). Half of the placebo-controlled studies used digestible carbohydrates as the placebo, which confounded findings for IL-6, glucose AUC, and insulin AUC. In conclusion, interventions with isolated and synthetic DFs resulted mainly in improved cholesterol concentrations and an attenuation of insulin resistance, whereas markers of dysglycemia and inflammation were largely unaffected. Although more research is needed to make reliable recommendations, a more targeted supplementation of DF with specific physicochemical properties at higher doses and for longer durations shows promise in enhancing several of its health effects.
观察性研究为膳食纤维(DF)摄入对健康的益处提供了有力证据;然而,补充分离的和合成的 DF 的人体干预研究结果并不一致。因此,我们进行了一项系统综述,以总结 DF 补充对健康成年人干预研究中免疫代谢疾病标志物的影响,并考虑了 DF 剂量、DF 物理化学特性、干预持续时间和使用的安慰剂的作用。从 1990 年到 2018 年,我们在五个数据库中搜索了评估 DF 对免疫代谢标志物影响的研究。合格的研究是那些补充分离或合成 DF 至少 2 周并报告基线数据以评估安慰剂效果的研究。共有 77 篇文献符合条件。DF 补充可使 36%-49%的干预措施中的总胆固醇(TC)、LDL 胆固醇、HOMA-IR 和胰岛素 AUC 降低。相比之下,只有不到 20%的干预措施降低了 C 反应蛋白(CRP)、IL-6、葡萄糖、胰岛素 AUC、HDL 胆固醇和甘油三酯。如果干预措施使用更高剂量的 DF(CRP、TC 和 LDL 胆固醇为 40%-63%)、粘性和混合植物细胞壁 DF(TC 和 LDL 胆固醇>50%)以及更长的干预时间(CRP 和葡萄糖为 50%),则更有可能显示出效果。有一半的安慰剂对照研究使用可消化碳水化合物作为安慰剂,这混淆了 IL-6、葡萄糖 AUC 和胰岛素 AUC 的发现。总之,用分离的和合成的 DF 进行干预主要导致胆固醇浓度的改善和胰岛素抵抗的减轻,而血糖和炎症的标志物则基本不受影响。尽管还需要更多的研究来提出可靠的建议,但用特定物理化学特性的 DF 进行更有针对性的补充,剂量更高、持续时间更长,有望增强其多项健康益处。